505 related articles for article (PubMed ID: 36683709)
21. Noncoding RNAs and Colorectal Cancer: A General Overview.
Sarraf JS; Puty TC; da Silva EM; Allen TSR; Sarraf YS; de Carvalho LEW; Adami F; de Oliveira EHC
Microrna; 2020; 9(5):336-345. PubMed ID: 33349228
[TBL] [Abstract][Full Text] [Related]
22. The ncRNA-TGF-β axis: Unveiling new frontiers in colorectal cancer research.
Alharbi KS
Pathol Res Pract; 2024 Feb; 254():155138. PubMed ID: 38266458
[TBL] [Abstract][Full Text] [Related]
23. Non-coding landscapes of colorectal cancer.
Ragusa M; Barbagallo C; Statello L; Condorelli AG; Battaglia R; Tamburello L; Barbagallo D; Di Pietro C; Purrello M
World J Gastroenterol; 2015 Nov; 21(41):11709-39. PubMed ID: 26556998
[TBL] [Abstract][Full Text] [Related]
24. MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.
Yao Y; Li N
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32270866
[TBL] [Abstract][Full Text] [Related]
25. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.
Fanale D; Castiglia M; Bazan V; Russo A
Adv Exp Med Biol; 2016; 937():207-28. PubMed ID: 27573902
[TBL] [Abstract][Full Text] [Related]
26. Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy.
Wei S; Hu W; Feng J; Geng Y
Cell Commun Signal; 2022 Sep; 20(1):150. PubMed ID: 36131281
[TBL] [Abstract][Full Text] [Related]
27. Circulating non-coding RNAs as new biomarkers and novel therapeutic targets in colorectal cancer.
Yang L; Zhang X; Hu G
Clin Transl Oncol; 2021 Nov; 23(11):2220-2236. PubMed ID: 34275108
[TBL] [Abstract][Full Text] [Related]
28. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
[TBL] [Abstract][Full Text] [Related]
29. Non-coding RNAs in Precursor Lesions of Colorectal Cancer: Their Role in Cancer Initiation and Formation.
Mohammadpour S; Noukabadi FN; Esfahani AT; Kazemi F; Esmaeili S; Zafarjafarzadeh N; Sarpash S; Nazemalhosseini-Mojarad E
Curr Mol Med; 2024; 24(5):565-575. PubMed ID: 37226783
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer.
Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
[TBL] [Abstract][Full Text] [Related]
31. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
32. Non-coding RNAs as emerging regulators and biomarkers in colorectal cancer.
Kishore C; Karunagaran D
Mol Cell Biochem; 2022 Jun; 477(6):1817-1828. PubMed ID: 35332394
[TBL] [Abstract][Full Text] [Related]
33. Role of non-coding RNAs as novel biomarkers for detection of colorectal cancer progression through interaction with the cell signaling pathways.
Esmaeili M; Keshani M; Vakilian M; Esmaeili M; Peymani M; Seyed Forootan F; Chau TL; Göktuna SI; Zaker SR; Nasr Esfahani MH; Ghaedi K
Gene; 2020 Aug; 753():144796. PubMed ID: 32450203
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.
Moradi Marjaneh R; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
IUBMB Life; 2019 Oct; 71(10):1428-1441. PubMed ID: 31322820
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis.
Zheng Z; Wu M; Li H; Xu W; Yang M; Pan K; Ni Y; Jiang T; Zheng H; Jin X; Zhang Y; Ding L; Fu J
BMC Med; 2023 Apr; 21(1):132. PubMed ID: 37013584
[TBL] [Abstract][Full Text] [Related]
36. ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
Zhang Z; Feng L; Liu P; Duan W
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30279206
[TBL] [Abstract][Full Text] [Related]
37. Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer.
Abu N; Hon KW; Jeyaraman S; Yahaya A; Abdullah NM; Mustangin M; Sulaiman SA; Jamal R; Ab-Mutalib NS
Epigenomics; 2019 Jun; 11(8):875-884. PubMed ID: 31020847
[No Abstract] [Full Text] [Related]
38. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer.
Wang JJ; Wang X; Song YX; Zhao JH; Sun JX; Shi JX; Wu ZH; Wang ZN
Dis Markers; 2019; 2019():2587109. PubMed ID: 31275444
[TBL] [Abstract][Full Text] [Related]
39. The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer.
Micallef I; Baron B
Noncoding RNA; 2021 Mar; 7(2):. PubMed ID: 33807355
[TBL] [Abstract][Full Text] [Related]
40. Non-coding RNAs Functioning in Colorectal Cancer Stem Cells.
Fanale D; Barraco N; Listì A; Bazan V; Russo A
Adv Exp Med Biol; 2016; 937():93-108. PubMed ID: 27573896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
